Oncology Venture ApS
We match patients and drugs.
Oncology Venture (OV) utilize a multi biomarker technology for the development of Precision Medicine via their mRNA Drug Response Predictor-DRP®. OV use the DRP® to select high likelihood responding patients for its pipeline of 6 focused anti-cancer drugs (liposomal platinum, PARPi, multi kinase inhibitor, a DNA repair drug and a GSHLiposomal doxorubicin) executed in phase 2 clinical trials in Breast, Prostate, Gynecology and Liver cancer.